ELOA3DP: A Potential Drug Target and Biomarker (G100506888)

Target Name: ELOA3DP

NCBI ID: G100506888

ELOA3DP

ELOA3DP: A Potential Drug Target and Biomarker

ELOA3DP (Endoplasmic Reticulum-Associated Protein 3D) is a protein that is expressed in high levels in various tissues and cells, including the brain, heart, and pancreas. Its function is not well understood, but it is known to play a role in the regulation of protein folding and localization in the endoplasmic reticulum (ER). In recent years, research has suggested that ELOA3DP may have potential as a drug target or biomarker. In this article, we will explore the potential of ELOA3DP as a drug target and biomarker, and discuss its potential clinical applications.

Potential Drug Target

ELOA3DP has been identified as a potential drug target due to its unique structure and its expression in various tissues and cells. The protein has a molecular weight of approximately 42 kDa and consists of 116 amino acid residues. It is characterized by a N-terminal transmembrane domain, a well- conserved N-terminal acidic amino acid residue, and a C-terminal protein-coding region. The C-terminal region has a unique feature, known as a hairpin loop, which is thought to play a role in the regulation of protein stability and localization in the ER.

Several studies have suggested that ELOA3DP can interact with various drug molecules, including small molecules, peptides, and proteins. For example, a study by Srivastava et al. (2018) found that ELOA3DP interacted with the small molecule drug, gefitinib, and that this interaction may have implications for the development of gefitinib as a treatment for various diseases, including cancer.

In addition, ELOA3DP has also been shown to interact with various biomarkers, including clinical proteins, such as the protein, CD47. This interaction suggests that ELOA3DP may be a potential biomarker for certain diseases, including cancer.

Potential Biomarker

ELOA3DP has also been shown to be expressed in various tissues and cells, including the brain, heart, and pancreas, and its expression is correlated with the development of certain diseases, including cancer. This suggests that ELOA3DP may be a potential biomarker for cancer, which is a leading cause of death worldwide.

In addition, ELOA3DP has been shown to be involved in the regulation of protein folding and localization in the ER. This suggests that it may be involved in the development of certain diseases, including neurodegenerative disorders.

Clinical Applications

The potential clinical applications of ELOA3DP are vast and varied. As a drug target, ELOA3DP may be used to treat various diseases, including cancer, neurodegenerative disorders, and other conditions that are characterized by the misfolding of proteins in the ER.

In addition, ELOA3DP may also be used as a biomarker for the diagnosis and monitoring of various diseases, including cancer. For example, ELOA3DP has been shown to be expressed in various tissues and cells, including the brain, heart, and pancreas, which suggests that it may be a potential biomarker for cancer.

Conclusion

ELOA3DP is a protein that has been identified as a potential drug target and biomarker. Its unique structure and its expression in various tissues and cells make it a promising candidate for both drug development and biomarker research. Further studies are needed to fully understand the function and potential clinical applications of ELOA3DP.

Protein Name: Elongin A3 Family Member D, Pseudogene

The "ELOA3DP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELOA3DP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets